JOHNSON & JOHNSON
Ticker: JNJHealthcarePharmaceutical PreparationsS&P 500The business
Johnson & Johnson (NYSE: JNJ) operates as a diversified healthcare company with approximately 138,200 full-time equivalent employees worldwide. The company maintains its corporate website at www.jnj.com and conducts business in virtually all countries globally, with a primary focus on products related to human health and well-being.
The company operates through two primary business segments: Innovative Medicine and MedTech. The Innovative Medicine segment focuses on pharmaceutical products across therapeutic areas including oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism. Key products in this segment include DARZALEX for multiple myeloma, STELARA for immunological conditions, TREMFYA for psoriasis and inflammatory bowel disease, and XARELTO for anticoagulation. DARZALEX and DARZALEX FASPRO collectively represent approximately 15.0% of total revenues, while STELARA accounts for approximately 6.5% and TREMFYA for approximately 5.5% of revenues.
The MedTech segment develops and manufactures products used in cardiovascular, orthopaedics, surgery, and vision care. This includes electrophysiology products, mechanical circulatory support technologies, neurovascular care solutions, joint reconstruction and trauma products, surgical instrumentation and robotic technologies, and vision care products marketed under the ACUVUE brand and TECNIS intraocular lenses. In October 2025, the company announced its intention to separate its Orthopaedics business, with targeted completion within 18 to 24 months.
The company operates 63 manufacturing facilities and sources from thousands of suppliers worldwide. Johnson & Johnson was incorporated in New Jersey in 1887 and maintains a global workforce distributed across multiple regions. The company's business model emphasizes innovation, with substantial investments in research and development, strategic collaborations, and licensing agreements. The company protects its intellectual property through extensive patent portfolios and trademark registrations across markets where it operates. Its competitive advantages include a diversified product portfolio, established distribution networks, strong brand recognition, and ongoing development of lifecycle management programs for existing products.
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- HQ
- NEW BRUNSWICK, NJ
- FY end
- 01-03
- CIK
- 200406
- SIC
- 2834
Ownership
Who holds JOHNSON & JOHNSON — across funds, superinvestors and bonds · N-PORT 2026Q2 · 13F 2026-06-30
Top fund holders
| Fund | % of fund | Value |
|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VTI · VANGUARD INDEX FUNDS | 0.84% | $19.41B |
| VANGUARD 500 INDEX FUND VOO · VANGUARD INDEX FUNDS | 0.95% | $15.84B |
| iShares Core S&P 500 ETF IVV · iShares Trust | 0.95% | $8.41B |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust SPY | 0.95% | $7.41B |
| Fidelity 500 Index Fund FXAIX · Fidelity Concord Street Trust | 0.84% | $6.95B |
Superinvestors in JOHNSON & JOHNSON
Share of each manager's reported 13F portfolio.
Bonds held by funds
Funds report holding 41 issues of JOHNSON & JOHNSON's debt, $2.68B at fund-held market value — what funds hold, not the company's debt outstanding. Weighted-average coupon 3.92%, maturing 2026–2060.
| Issue | Coupon | Matures | Funds | Fund-held |
|---|---|---|---|---|
| JOHNSON&JOHNSON | 4.850% | 2032-03-01 | 43 | $211.56M |
| Johnson & Johnson | 5.000% | 2035-03-01 | 50 | $186.90M |
| JNJ 2.9 01/15/28 | 2.900% | 2028-01-15 | 38 | $182.84M |
| JOHNSON&JOHNSON | 4.900% | 2031-06-01 | 49 | $151.80M |
| Johnson & Johnson | 4.800% | 2029-06-01 | 44 | $148.50M |
| JOHNSON&JOHNSON | 4.700% | 2030-03-01 | 37 | $144.19M |
| Johnson & Johnson | 4.950% | 2034-06-01 | 41 | $130.54M |
| Johnson & Johnson | 1.300% | 2030-09-01 | 42 | $120.20M |
| JOHNSON&JOHNSON | 3.700% | 2046-03-01 | 44 | $110.96M |
| JOHNSON&JOHNSON | 4.375% | 2033-12-05 | 32 | $103.34M |
The 10 largest by fund-held value, of 41.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Go deeper in your own AI
15 years of statements, narrative and filings — queryable over MCP.
Professionals can also use the built-in AI chat (subscription + your own Anthropic key).
15 years of JOHNSON & JOHNSON's financials
Income statement, balance sheet and cash flow across 15 years, every filing with its disclosures, and each number traceable to the filing it came from — free with an account, no card required.
Sign in free